Jazz Pharmaceuticals, Inc.
NEWS
Life sciences news sometimes flies under the radar. So here’s a look at a few stories you may have missed.
Jazz Pharmaceuticals will beef up its neurology pipeline with a $7.2 billion buyout of GW Pharmaceuticals, the only company yet to score U.S. regulatory approval for a cannabis-derived product.
Here’s a look at some of the stories that emerged from the conference on Wednesday.
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
The U.S. Food and Drug Administration (FDA) approved Xywav, the first new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years.
Wrapping up the month of July, there are three PDUFA dates on the U.S. Food and Drug Administration (FDA) calendar.
The approval was based on monotherapy clinical data from a trial in 105 adults with SCLC whose disease progressed after platinum-based chemotherapy.
Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers.
The following is a roundup of some of this week’s non-coronavirus biopharma news.
JOBS
IN THE PRESS